The October 4, 2022 issue of Nikkei Xtech published the following article.
“AI drug discovery company Elix is collaborating with a biotech startup from Takeda, utilizing a wealth of binding compound data.”
In this joint research, Elix will incorporate SEEDSUPPLY’s wealth of data, particularly its data on key drug discovery targets such as membrane proteins, into the AI’s learning, and advancing the establishment of technology for using in silico techniques to screen for compounds with superior properties.
Please refer to the following news releases of Elix for more details.
“AI drug discovery company Elix commences joint research with proprietary screening technology holder SEEDSUPPLY”